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Background: Selective and reversible inhibitors of human Cathepsin K (CatK), including odanacatib (ODN), have
been developed as potential therapeutics for the treatment of osteoporosis. Inhibitors of human CatK show
significantly less potency for the rodent enzymes compared with that for the human or rabbit enzymes; thus the
Schenk model in growing rabbit was developed as a screening assay for the in vivo activity of CatK inhibitors in
blocking bone resorption.
Methods: In this study, the efficacy of the selective inhibitors L-833905, L-006235, L-873724, and L-1037536 (ODN)
of human CatK in the rapidly growing rabbit ‘Schenk’ model (age seven weeks) was compared to vehicle, using the
bisphosphonate, alendronate (ALN), as a positive control, to assess inhibition of bone resorption. An enzyme
inhibition assay (EIA) and an in vitro bone resorption assay using rabbit osteoclasts on bovine cortical bone slices
were performed to evaluate the potency of these CatK inhibitors. Bone mineral density of the distal femur (DFBMD)
was measured after ten days of treatment using ex vivo DXA densitometry.
Results: Results of the EIA using rabbit CatK and the rabbit bone resorption assay showed that three of the four
compounds (L-006235, L-873724, and ODN) had similar potencies in the reduction of collagen degradation.
L-833905 appeared to be a weaker inhibitor of CatK. Taking into account the respective in vitro potencies and
pharmacokinetic profiles via oral administration, the efficacy of these four CatK inhibitors was demonstrated in a
dose-related manner in the growing rabbit. Significant increases in DFBMD in animals dosed with the CatK
inhibitors compared to vehicle were seen.
Conclusions: Efficacy of the CatK inhibitors in the Schenk rabbit correlated well with that in the in vitro rabbit bone
resorption assay and in the ovariectomized rabbit model as previously published. Hence, these studies validated the
rabbit Schenk assay as a rapid and reliable in vivo model for prioritizing human CatK inhibitors as potential
therapeutic agents.
Keywords: Odanacatib, Cathepsin K inhibitor, Osteoclast, Antiresorptives, DXA, Rabbit Schenk assay,
Postmenopausal osteoporosisBackground
The lysosomal cysteine protease, Cathepsin K (CatK), is
predominantly expressed in osteoclasts [1] and has an im-
portant role in the degradation of the demineralized colla-
gen matrix components of bone (predominantly Type-I
collagen) at neutral and acidic pH [2]. Genetic confirmation
for a role of CatK in bone resorption exists in the form of
pycnodysostosis, a rare human genetic disease linked to
several loss-of-function mutations in the CatK gene* Correspondence: le_duong@merck.com
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distribution, and reproduction in any mediumcharacterized by high bone mineral density (BMD), acroos-
teolysis of the distal phalanges, short stature, and skull
deformities with delayed suture closure [3-5]. Mice with
gene deletion of CatK show impaired osteoclastic resorp-
tion which leads to osteopetrosis [6]. These mice display
higher bone mass in both cortical and trabecular bone,
greater trabecular and cortical thickness, and normal bone
strength [7,8]. Mice overexpressing CatK show a decrease
in trabecular bone volume of the distal femoral metaphyses
and accelerated bone turnover [9]. Based on its substrate
preference, cellular distribution, and genetic evidence, CatK
is likely to play an important role in bone resorption.entral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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rently in development for the treatment of osteoporosis [10].
The preferred small animal model for evaluation of the
efficacy of bone therapeutics is the ovariectomized (OVX)
skeletally mature rat [11]. The utility of the OVX rat is
limited by significant interspecies sequence variation (88%
homology) in key residues within the active site of human
and rat CatK enzymes [12]; inhibitors of human CatK have
significantly lower potency against the rodent CatK
enzyme to be reliably tested for bone effects in the rat or
mouse model. In contrast, rabbit CatK shares 96%
sequence identity and 99% similarity with its human
counterpart with only two amino acid differences in the
active site [12,13]. Therefore, the selection of rabbit as the
preclinical species for in vivo screening assay for CatK
inhibitors was due to the species differences in response
to this class of bone resorption inhibitors. The differences
in homologies between rat, rabbit and human CatK are
derived from inhibitor potencies. For example, ODN is
highly potent versus human and rabbit CatK (half
maximal inhibitory concentration [IC50 ]= 0.2 and 1 nM,
respectively) but more than 500-fold less potent versus rat
CatK (IC50 = 112 nM) or mouse CatK (IC50 = 108 nM)
[14]. Our work with the adult OVX rabbit shows that it is
a relevant in vivo bone model for testing selective inhibi-
tors of the human CatK enzyme [13]. However, the
estrogen-deficient OVX model in skeletally mature rab-
bits requires approximately six months to achieve pre-
dictable and measurable bone loss by dual energy x-ray
absorptiometry (DXA) [15]. Due to the long duration of
the adult OVX rabbit model and the relatively large size
of adult rabbits (3.5 kg), the use of the adult OVX rabbit
model for quick in vivo screening and selection of com-
pounds with limited drug quantity in the early pre-
clinical phase is impractical.
A rapidly growing rabbit model has been developed for
in vivo prioritization of CatK inhibitors before testing in
the OVX rabbit assay. Development of this growing rabbit
model is based upon the growing rat model used for test-
ing the anti-resorptive efficacy of the bisphosphonates
[16-18]. This model is often referred to as the “rat Schenk
assay.” This assay relies upon inhibiting the process of bone
resorption in rapidly growing animals at the periosteal sur-
face (the “funnel region”) of the metaphysis, and the aspect
of metaphyseal trabeculae in the marrow cavity that is op-
posite to the nearby epiphyseal growth cartilage. Inhibiting
the removal of calcified cartilage by resorption in the pri-
mary spongiosa is also an important target. In early work,
treatment of growing rats treated with the first-generation
bisphosphonates, etidronate or clodronate, for ten days
resulted in higher trabecular bone volume in the proximal
tibial metaphysis of treated compared to untreated rats
[16,17]. A more recent experiment showed increased tra-
becular bone volume following seven days of subcutaneous(SC) alendronate (ALN) (0.010 mg/kg/d) [18]. Furthermore,
a more recent study using weanling rats showed an increase
in distal femoral metaphyseal BMD following six weeks of
once-weekly treatment with ALN [19]. A higher growth
rate of the distal and proximal femur, the proximal tibia,
and the proximal and distal radius has been observed in the
rapidly growing rabbit than that typically observed with
other species or in more mature animals [20,21].
The primary objective of the current study was to
determine if the rapidly growing rabbit (“rabbit Schenk
assay”) could be used to quantify and prioritize CatK
inhibitors according to their respective potencies in
inhibiting bone resorption in vivo. The model was first
characterized by dose titrating ALN and determining
areal BMD of the distal femur (DFBMD) using ex vivo
DXA. Next, the efficacy of four relatively potent CatK
inhibitors with varied chemical structures, in vitro
potency, and in vivo pharmacokinetic profiles was
assayed in a similar fashion.
Methods
Animals
Six- to seven-week-old female New Zealand White (NZW)
rabbits (Covance Research Products, Denver, PA, USA),
weighing approximately 1.35–1.5 kg were received. The
rabbits were kept in wire-bottomed cages under standard
laboratory conditions with lighting set for 12 h light, 12 h
dark per 24 h, a constant temperature of 21 ± 3°C, relative
humidity 50 ± 20%, and 10–15 air changes per hour.
Rabbits received a standard pelleted diet (High Fiber Lab
Rabbit Diet 5326, PMI Nutrition International, Brentwood,
MO, USA), with water ad libitum. Animal experiments
were reviewed and approved by the Institutional Animal
Care and Use Committees at Merck Frosst Center for
Therapeutic Research (Montreal, Quebec, Canada) and
Merck Research Laboratories (West Point, PA, USA).
Dose-ranging ALN in growing rabbits
To characterize the dose of ALN required to show in-
creases in DFBMD, dose-ranging studies were conducted
using ALN, administered at doses of 0, 50, 100, 200, and
500 μg/kg (SC, once daily). Seven-week-old rabbits were
weight-randomized into groups (n = 8-11 per group). ALN
was prepared in deionized water and pH adjusted to 7.2.
The injection volume was 0.3 mL per rabbit. Rabbits were
treated daily for 10 consecutive days. Rabbits were
reweighed on Day 6 and dosing volume was adjusted ac-
cordingly. At necropsy, the right femur was excised and
stored in 70% ethanol.
CatK inhibitor screening
Rabbits were treated once daily by oral gavage for 10
consecutive days with vehicle (1% carboxymethyl-
cellulose or 0.5%/0.2% carboxymethylcellulose/SDS),
Pennypacker et al. BMC Musculoskeletal Disorders 2013, 14:344 Page 3 of 9
http://www.biomedcentral.com/1471-2474/14/344CatK inhibitors, or ALN (100 μg/kg, SC). Several studies
were conducted, with each study including vehicle
(n = 11–14), multiple dose levels of a CatK inhibitor
(n = 13–14 per group), and ALN (n = 8–9). On Day 1,
two rabbits from each group receiving CatK inhibitors
were bled via the central ear artery (0.5 mL each) at 0,
0.25, 1, 3, 6, 8, and 24 h after dosing. Plasma concentra-
tions of CatK inhibitors were determined in all samples.
On Day 11, rabbits were euthanized. Femurs were
removed and stored in 70% ethanol for BMD analysis.Enzyme inhibition assay (EIA)
Enzyme activity assays were carried out using rabbit
CatK as previously described [22]. Briefly, the assay was
carried out in 2-(N-morpholino) ethanesulfonic acid
50 mM pH 5.5 containing dithiothreitol 2.5 mM, ethyl-
enediaminetetraacetic acid 2.5 mM, and 10% dimethyl
sulfoxide. Prior to the addition of substrate, different
concentrations of the inhibitor ranging from 100 μM to
0.2 nM were pre-incubated for 15 min with each en-
zyme (0.2–1 nM) to allow the formation of the enzyme-
inhibitor complex. Substrate was then added and the
enzyme activity measured from the increase of fluores-
cence at 460 nm 355 nm. The final volume of the reac-
tion was 100 μL. Assays were performed in 96-well
plate format and the plate was read using a Spectramax
(Molecular Devices) plate reader. The percentage inhib-
ition of the reaction was calculated from a control reac-
tion containing only vehicle. IC50 curves were generated
by fitting percentage inhibition values to a four-
parameter logistic model (SOFTMAX PRO, Molecular
Devices, Sunnyvale, CA, USA).Bone resorption assay
The bone resorption assay is a functional in vitro assay
that measures Type-I collagen degradation after a three-
day incubation of rabbit osteoclasts cultured on bovine
bone with varying concentrations of test compound, as
previously described [23]. Briefly, long bones isolated
from a 10-day-old NZW rabbit were finely minced in
alpha-minimal essential medium (α-MEM) (Gibco BRL;
Gaithersburg, MD, USA) containing penicillin/strepto-
mycin, pH 7.1 to obtain a cell suspension and 1 × 106
cells were seeded onto each 6 mm diameter × 0.22 mm
thick bovine bone slice in the same medium containing
2% fetal bovine serum (FBS). After 4 h, the medium was
replaced with α-MEM, 2% FBS, 1,25(OH)2D3 10 nM,
and test compounds. The cultures were incubated for
three days at 37°C in 5% CO2. C-telopeptide of Type-I
collagen (CTx-I) released into the medium was mea-
sured by the CROSSLAPS Elisa assay (Osteometer Bio-
tech, Herlev, Denmark).BMD analysis
Whole right femurs with muscles removed, were immersed
in two inches of water in an acrylic box, and positioned
with both distal condyles resting on the bottom of the box.
The distal 5 cm of the femur was scanned using small ani-
mal software in high resolution mode on a Hologic QDR
4500 fan-beam bone densitometer (DXA; Hologic, Inc.,
Waltham, MA, USA). The distal 3 cm of the femur was an-
alyzed. A region of interest (ROI) beginning one line distal
to the distal edge of the femur and centered 70 lines wide
and extending 60 lines proximally in the long axis of the
bone was applied. Bone mineral content (BMC) and bone
area (BAr) were output by DXA software. BMD was calcu-
lated as BMC/BAr.
Histological examination of distal femur
Following ex vivo DXA scanning, the distal one-third of
the femur was cut mid-sagitally and then dehydrated,
without prior decalcification, in increasing concentra-
tions of ethanol. The right portion was embedded in
80% methylmethacrylate/20% dibutyl phthalate. Parasag-
ittal sections (6 μm) were cut on a Reichert-Jung Polycut
sledge microtome (Nussloch, Germany) and mounted on
glass slides. A Masson’s trichrome stain was performed
to view calcified tissue.
Statistical analysis
For dose-ranging ALN and CatK inhibitor L-833905 stud-
ies, DFBMD differences of treatment groups compared to
vehicle were analyzed by Kruskal-Wallis non-parametric
analysis of variance (ANOVA) with Student-Neuman-
Keuls post hoc testing. Differences were considered signifi-
cant when p ≤ 0.05. All comparisons were made using
CRUNCH software (JanDel Corp.; San Jose, CA, USA).
For all other studies of CatK inhibitors, statistical compu-
tation of DFBMD data was performed using Statview
(SAS Institute, Inc., Cary, NC). Differences among treat-
ment groups were tested by one-way ANOVA. If signifi-
cant differences were indicated by ANOVA, comparison
between group means was tested by Fisher’s partial least-
squares difference for post hoc analysis. Differences were
considered significant when p ≤ 0.05.Results
Characterization of the rabbit Schenk model in
growing rabbits
Early characterization of the rabbit Schenk model included
dose titration of ALN and suitable CatK inhibitors devel-
oped early in the screening program. Experiments using
ALN at 50, 100, 200, or 500 μg/kg/day SC for ten consecu-
tive days showed significant increases in DFBMD above
vehicle, ranging from 15% at 50 μg/kg/day (p < 0.01) to
21% at 500 μg/kg/day (p < 0.001) (Table 1).
Table 1 Effect of 10 days' ALN treatment on DFBMD in
growing rabbits
ALN dose (μg/kg) DFBMD (mg/cm2) % BMD gain
Veh ALN
50 241.4 ± 9.2 277.8 ± 8.4** 15
100 270.5 ± 7.9 313.7 ± 3.9*** 16
200 242.0 ± 3.4 281.7 ± 6.4*** 16
500 241.6 ± 5.2 291.2 ± 9.4*** 21
Mean ± standard error of the mean; **p < 0.01, ***p < 0.001 vs. vehicle.
ALN = alendronate, DFBMD = distal femoral bone mineral density,
Veh = vehicle.
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varied by an order of magnitude, established the “rabbit
Schenk assay” as one that could assess anti-resorptive effi-
cacy, by testing an established osteoporosis treatment
agent that had been previously tested in the rat Schenk
assay [18]. ALN 100 μg/kg/day was selected as a reliable
positive control for subsequent studies that tested CatK
inhibitors in growing rabbits.
We also histologically examined the treatment-related
effects of bone resorption inhibitors, including both ALN
and a CatK inhibitor that was selected as a tool compound
from an early chemical series of the screening program
(Figure 1). The metaphyseal region of a rapidly growing
rabbit showed high levels of modeling associated with calci-
fied cartilage septae and trabecular bone (Figure 1a&b).
Treatment with either ALN (Figure 1c&d) or a CatK inhibi-
tor (Figure 1e&f) resulted in increased retention of both cal-
cified cartilage and bone tissue, when compared to vehicle
treatment. No obvious morphological changes in the growth
plate, cortical bone and bone marrow were noted in animals
treated with these bone resorption inhibitors for 10 days.
Evaluation of in vivo efficacy of potent CatK inhibitors
Selection of CatK inhibitors based on in vitro potencies
We highlight here four CatK inhibitors selected for
validation in the rabbit Schenk assay, based on their
in vitro profiles. Table 2 summarizes the IC50 values of
the CatK inhibitors: L-833905 ((R)-N-(cyanomethyl)-
4-methyl-2-(4′-(piperazin-1-yl)-[1,1′-biphenyl]-3-yl)penta-
namide) [24], L-006235 [13], L-873724 [25] and
L-1037536 (ODN) [25] tested against rabbit CatK using
2 μM of Z-Leu-Arg-AMC as substrate [13,25]. IC50 values
for the same compounds in the functional bone resorption
assay are also shown in Table 2 [13,25]. In the functional
bone resorption assay, L-006235, L-873724, and ODN
were potent inhibitors of bone resorption in vitro. These
three compounds were approximately 30-fold more potent
in the bone resorption assay than L-833905 [13,25].
Though potencies obtained in the bone resorption assay
were reduced by an approximate 5–20-fold shift relative
to those in the enzymatic assay, the same rank order of
potencies was maintained.Pharmacokinetic evaluation of CatK inhibitors in
growing rabbits
Doses of the respective CatK inhibitors for the rabbit
Schenk assays were selected on the basis of trough plasma
levels (Cmin) following oral dosing in the same species. As
indicated in Table 2, the mid-dose of all inhibitors, except
L-833905, provided trough plasma levels that remained at
or above the rabbit bone resorption IC50 for the duration
of the study (i.e. Cmin at 24 h following oral dose ≥ bone
resorption IC50 or [Cmin]/bone resorption IC50 ≥ 1). For
both doses of L-833905 and the lowest dose of L-873724,
the plasma levels dropped below the bone resorption IC50
at 24 h (Table 2). Although ODN was slightly less potent
compared to L-006235 and L-873724 in the bone resorp-
tion assay, lower doses were selected due to its longer
rabbit plasma half-life which thereby provided higher Cmin
plasma levels at 24 h post-dosing.
Effects of CatK inhibitors on distal femoral BMD (DFBMD)
Table 3 shows DFBMD values in response to dosing with
three CatK inhibitors. Rabbits treated with ALN had
significantly higher DFBMD than vehicle in each experi-
ment. DFBMD with L-833905 was numerically higher at
10 mg/kg (3%, NS) and significantly higher at 30 mg/kg
(10%, p < 0.01). Treatment with 1 mg/kg L-006235 re-
sulted in a statistically significant increase in DFBMD (7%,
p < 0.01), while the 3 and 10 mg/kg groups showed robust
increases in DFBMD (11% and 15%, respectively, both
p < 0.001). Rabbits treated with L-873724 had higher
DFBMD at 3 (9%, p < 0.01) and 10 mg/kg (15%, p < 0.001)
than vehicle. ODN treated rabbits had higher DFBMD,
that was significantly greater than vehicle at 0.3 (7%,
p < 0.01), 1 (11%, p < 0.001), and 3 mg/kg (19%, p < 0.001)
(Figure 2). Figure 3 highlights the increases in DFBMD by
both ALN and ODN compared to vehicle control.
Discussion
CatK is predominantly expressed in osteoclasts [1], and
has an important role in the degradation of the collagen
matrix components of bone (predominantly Type-I colla-
gen) at acidic pH. Based on human genetics [3-5], experi-
mental genetics in mice [6], substrate preference, and
cellular distribution, the pivotal role of CatK in osteoclastic
bone resorption has been demonstrated. These findings
have led to the development of pharmacologic inhibitors of
CatK to treat diseases characterized by high bone turnover
such as osteoporosis.
In this report, four CatK inhibitors, L-833905, L-006235,
L-873724, and ODN, were evaluated for their effects on
DFBMD in the rapidly growing rabbit. Based on their re-
spective pharmacokinetic profiles in rabbits and their
in vitro profiles, these compounds were chosen to evaluate
in vivo anti-resorptive efficacy. These four compounds,
when administered daily for 10 consecutive days to














Rabbit CatK Rabbit bone resorption assay
L-833905 10 1.9 163 29 – 0.2 33 ± 2 149 ± 20
30 6.1 651 60 0.4
L-006235 1 0.3 74 9 113 1.8 0.5 5 ± 1
3 1.0 337 15 3.0
10 5.0 2436 8 1.6
L-873724 1 0.5 78 <LOD* 26 ≤0.1 0.8 13 ± 1
3 3.1 490 28 2.2
10 7.8 1370 32 2.5
ODN 0.3 0.7 33 35 6 1.5 1.0 23 ± 6
1 2.2 130 37 1.6
3 4.1 270 88 3.8
* ~ 1 nM.
AUC = area under the curve, CatK = Cathepsin K, Cl = clearance, Cmax = maximum concentration after dosing, Cmin = minimum concentration after dosing,
IC50 = half maximal inhibitory concentration, LOD = limit of detection, ODN = odanacatib, res = resorption.
Reprinted (adapted) with permission from Falgueyret et al. 2005 [13].









Figure 1 Increased retention of calcified cartilage and bone in response to treatment with CatK inhibitor or ALN. Representative
histological images of distal femoral region from rabbits treated with (a, b) vehicle, (c, d) alendronate, and (e, f) a cathepsin K inhibitor for
10 days are shown. Distal femurs (a, c and e) and their metaphysis regions (b, d and f) are shown at 0.5X and 1X, respectively. Bone, blue
trabecular spicules; BM, bone marrow; GP, growth plate. Scale bar = 1 mm.
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Table 3 Distal femur BMD (mg/cm2) in three rabbit Schenk assays
Compound Vehicle Dose ALN
1 mg/kg 3 mg/kg 10 mg/kg 30 mg/kg
L-833905 274.3 ± 4.5 – – 282.5 ± 5.5 301.8 ± 4.9** 314.0 ± 9.1**
L-006235 263.3 ± 4.5 281.7 ± 4.9** 293.5 ± 2.8*** 303.5 ± 5.4*** – 300.5 ± 4.6***
L-873724 285.5 ± 5.4 301.2 ± 3.7 310.5 ± 6.5** 327.7 ± 7.5*** – 352.8 ± 9.4***
Mean ± standard error of the mean; **p < 0.01, ***p < 0.001 vs. vehicle.
ALN = alendronate, BMD = bone mineral density.
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vehicle treatment in a dose-dependent fashion, showing
that inhibitors of the CatK enzyme inhibit bone resorption
in vivo, as predicted by their respective potencies in the
EIA and the in vitro bone resorption assay, and their phar-
macokinetic profile in rabbits.
From the EIA and functional cell-based assay, L-006235,
L-873724, and ODN were selected as potent inhibitors of
CatK-mediated activity of rabbit osteoclasts in the degrad-
ation of Type-I collagen in vitro. L-833905 was a 6–30-
fold less potent inhibitor of CatK than the above three
compounds. The rank order of potencies of these inhibi-
tors in the bone resorption assay tracked well with that in
the EIA. The shift in potencies between the two assays
may reflect the degree of protein binding of the inhibitors
and high fractional inhibition of CatK required to inhibit
bone resorption in osteoclasts [13,25]. Moreover, the
potencies of these compounds were also dependent on
their ability to penetrate and exit the resorption lacunae
and lysosomes of osteoclasts during resorption [26].
Based on our historical database, inhibitors of the
human CatK enzyme are about two orders of magnitude
less active in inhibition versus the rat CatK enzyme. The



















Figure 2 Relationship between treatment with ODN or ALN and DFBM
rabbit model. Mean ± standard error of the mean; ALN = alendronate, DFBCatK versus other rat cathepsins has been shown to be
challenging [27,28]. However, human CatK inhibitors are
generally effective in the rabbit, usually displaying only
approximately 5-fold less potency toward the rabbit
enzyme. These findings are supported by the higher amino
acid sequence homology between human and rabbit
enzymes. These fundamental interspecies differences in
CatK led us to select the growing rabbit as a relatively
small size animal model, which can be used to rapidly
identify in vivo anti-resorptive activity of numerous CatK
inhibitors prior to the evaluation of selected candidates in
the long-term OVX model of postmenopausal osteoporosis
in the adult rabbit or non-human primate (NHP).
The growing rabbit has several advantages, including a
higher bone growth rate than that typically observed with
other laboratory large species such as dog, pig or monkey,
which have been used previously to evaluate therapeutic
agents for osteoporosis [20,21]. We previously described
the development of the adult OVX rabbit assay to assess
the efficacy of CatK inhibitors on preventing estrogen defi-
ciency bone loss in the lumbar vertebrae and distal femur
[15]. However, the adult OVX rabbit model has many lim-
itations which preclude its use for routine drug screening,






D. Treatment with ODN or ALN increased DFBMD in the growing
MD = distal femur bone mineral density, ODN = odanacatib.
ba c
Figure 3 Representative DXA images of the rabbit distal femur after 10 days' treatment with ALN or ODN. Note increased density of
secondary spongiosa with ALN or ODN as compared to vehicle. (a) vehicle (DFBMD = 263 mg/cm2), (b) ALN (DFBMD = 361 mg/cm2), and
(c) ODN 3 mg/kg (DFBMD = 388 mg/cm2). ALN = alendronate (100 μg/kg/day), DFBMD = distal femur bone mineral density, DXA = dual energy
x-ray absorptiometry, ODN = odanacatib.
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duration and a large body weight that requires preparation
of large quantities of agents. An NHP in vivo screening
assay examining markers of bone resorption, (e.g. serum
CTx, collagen Type-I N-telopeptides) [27,29] also has dis-
advantages, including availability of trained personnel, long
washout periods, high demand for drug quantity, high cost,
and limited numbers of skeletally mature NHPs available
for drug screening purposes.
Thus, a short-term reliable in vivo screening assay
to quickly assess potencies of compounds for further
optimization was highly valuable for a drug screening pro-
gram. The current study is the first to report the use of
the rapidly growing rabbit as an assay for in vivo activity
of bone resorption inhibitors, with similar fundamental
characteristics to that previously used in growing rats
[16-18,30,31]. Unlike the adult OVX rabbit, this model re-
quires only 10 days of dosing. Considering that the assay
itself is 18 times shorter in duration and the weight of the
animals during the assay is 40% of those used in the adult
OVX rabbit model, the total requirement for compound is
40-fold less than that needed for an adult OVX rabbit
study. Efficacy of the bone resorption inhibitors is assessed
by ex vivo DXA of the distal femur, a region that contains
an active epiphyseal growth cartilage in growing rabbits.
During longitudinal growth, the structure and density of
metaphyseal trabecular bone relies on a well-controlled
balance between calcified cartilage formation in the zone
of cell hypertrophy of the epiphyseal growth cartilage,
bone deposition in the primary and secondary spongiosa,
and the removal of both calcified cartilage and bone in
both the primary and secondary spongiosa. Inhibition of
calcified tissue resorption during growth without effects
on chondrocyte activity in the epiphyseal growth cartilage
results in a density increase in the primary and secondary
spongiosa that is characterized by higher trabecular
number. The higher trabecular number is due to an
increase in the number of persisting calcified cartilagesepta upon which new bone tissue is deposited. Bispho-
sphonates increase metaphyseal trabecular bone volume
and trabecular number in the proximal tibial metaphysis
of the growing rat [16-18,30,31]. In addition, when non-
decalcified histologic sections are used, the rat Schenk
assay becomes useful for screening for the existence of
mineralization defects [16,17].
The results of these rabbit Schenk studies suggest that
potent and orally active CatK inhibitors are effective as
bone resorption inhibitors in vivo. This assay can be
used to quickly rank order potencies of the CatK inhibi-
tors prior to their evaluation in estrogen deficiency-
related bone-loss studies. In fact, efficacy of the CatK
inhibitors L-006235 and ODN were further demon-
strated in adult OVX rabbits [15] and ODN in OVX
NHPs [32,33].Conclusions
The rabbit Schenk assay is a valid, consistent in vivo
screen for two classes of bone resorption inhibitors,
CatK inhibitors and bisphosphonates. The current data
confirm the efficacy of four different selective CatK
inhibitors and ALN in reducing bone resorption in vivo
in the rapidly growing rabbits. The results for CatK
inhibitors were well-correlated with those in the in vitro
bone resorption assay. The Schenk assay results testing
L-006235 and odanacatib predict the outcome of tests
of the same agents on estrogen deficiency-induced bone
loss in both skeletally mature rabbit [14] and monkey
models [32]. Therefore, while the OVX animal model is
the standard method for assessing efficacy and long-
term effects of anti-osteoporosis agents on bone quality,
we demonstrated that the rabbit Schenk assay can serve as
a rapid, cost-effective, and reliable test for evaluation of
numerous bone resorption inhibitors prior to the evalu-
ation of a few selected candidates in the long-term OVX-
model of the same species or non-human primates.
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